Mark Allen, D.D.S.; Decision and Order
DEA revoked Mark Allen, D.D.S.'s registration for failing to maintain effective controls against diversion of controlled substances, including inadequate recordkeeping and failure to report theft/loss. This signals heightened enforcement against individual practitioners and underscores the importance of robust diversion prevention programs.
Aforeworn detected this change in the Pharmacy & Controlled Substances space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies, and any DEA registrant handling controlled substances. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Immediately; ongoing compliance expected.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmacy & Controlled Substances continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
DEA reaffirms that failure to implement adequate diversion controls (e.g., recordkeeping, suspicious order monitoring, theft reporting) can result in registration revocation.
Who it affects
Independent pharmacies, retail chains, compounding pharmacies, long-term-care pharmacies, and any DEA registrant handling controlled substances.
What you must do
Review and strengthen your controlled substances diversion prevention program, including recordkeeping, suspicious order monitoring, and theft/loss reporting procedures.
Deadline
Immediately; ongoing compliance expected.
Source: https://www.federalregister.gov/documents/2026/07/10/2026-13989/mark-allen-dds-decision-and-order
Never miss a change like this again
Aforeworn watches Pharmacy & Controlled Substances around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmacy & Controlled Substances
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
- Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
- Amanda Ward, N.D.; Decision and Order